These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10941154)

  • 21. Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck.
    Suntharalingam M; Haas ML; Van Echo DA; Haddad R; Jacobs MC; Levy S; Gray WC; Ord RA; Conley BA
    Cancer; 2001 Feb; 91(3):548-54. PubMed ID: 11169937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
    Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
    Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
    Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
    Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of planned neck dissection for the N2-N3 neck after chemoradiation for locally advanced squamous cell carcinoma of the head and neck.
    Lau H; Phan T; Mackinnon J; Matthews TW
    Arch Otolaryngol Head Neck Surg; 2008 Mar; 134(3):257-61. PubMed ID: 18347249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience.
    Gupta T; Agarwal JP; Ghosh-Laskar S; Parikh PM; D'Cruz AK; Dinshaw KA
    Head Neck Oncol; 2009 Jun; 1():17. PubMed ID: 19527507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized phase II trial of concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin for squamous cell carcinoma of the head and neck.
    Homma A; Shirato H; Furuta Y; Nishioka T; Oridate N; Tsuchiya K; Nagahashi T; Aoyama H; Inuyama Y; Fukuda S
    Cancer J; 2004; 10(5):326-32. PubMed ID: 15530262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer.
    Balm AJ; Rasch CR; Schornagel JH; Hilgers FJ; Keus RB; Schultze-Kool L; Ackerstaff AH; Busschers W; Tan IB
    Head Neck; 2004 Jun; 26(6):485-93. PubMed ID: 15162349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
    Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma.
    de Castro G; Snitcovsky IM; Gebrim EM; Leitão GM; Nadalin W; Ferraz AR; Federico MH
    Eur Arch Otorhinolaryngol; 2007 Dec; 264(12):1475-82. PubMed ID: 17643256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study.
    Leyvraz S; Pasche P; Bauer J; Bernasconi S; Monnier P
    J Clin Oncol; 1994 Sep; 12(9):1876-85. PubMed ID: 8083711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck : Final 5‑year results of a phase II study.
    Kuhnt T; Schreiber A; Pirnasch A; Hautmann MG; Hass P; Sieker FP; Engenhart-Cabillic R; Richter M; Dellas K; Dunst J
    Strahlenther Onkol; 2017 Sep; 193(9):733-741. PubMed ID: 28500491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pegulated liposomal doxorubicin and cisplatin given concurrently with conventional radiotherapy: a phase I dose-escalation trial for patients with squamous cell carcinoma of head and neck and lung.
    Varveris H; Kachris S; Mazonakis M; Lyraraki E; Markouizou A; Karabekios S; Tzedakis A; Perisinakis K; Damilakis J; Vlachaki M
    Oncol Rep; 2004 Aug; 12(2):473-81. PubMed ID: 15254718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).
    Ghadjar P; Simcock M; Zimmermann F; Betz M; Bodis S; Bernier J; Studer G; Aebersold DM;
    Radiother Oncol; 2012 Aug; 104(2):213-8. PubMed ID: 22726581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative chemotherapy-sensitized radiation therapy for cervical metastases in head and neck cancer.
    Puc MM; Chrzanowski FA; Tran HS; Liu L; Glicksman AS; Landman C; Slotman GJ
    Arch Otolaryngol Head Neck Surg; 2000 Mar; 126(3):337-42. PubMed ID: 10722006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol.
    Abitbol A; Abdel-Wahab M; Lewin A; Troner M; Rodrigues MA; Hamilton-Nelson KL; Markoe A
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):942-7. PubMed ID: 12095561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative study of concomitant boost radiation versus concomitant boost with concurrent chemoradiation versus standard fractionation chemoradiation in locally advanced head-and-neck cancer.
    Gupta P; Dhull AK; Kaushal V
    J Cancer Res Ther; 2020; 16(3):478-484. PubMed ID: 32719254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data.
    Specenier PM; Van den Weyngaert D; Van Laer C; Weyler J; Van den Brande J; Huizing MT; Dyck J; Schrijvers D; Vermorken JB
    Ann Oncol; 2007 Nov; 18(11):1856-60. PubMed ID: 17823386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.